期刊文献+

抑癌基因PTEN在非小细胞肺癌中的表达研究 被引量:1

Expression of PTEN in non-small-cell lung carcinoma
下载PDF
导出
摘要 目的探讨抑癌基因PTEN表达与非小细胞肺癌(non-small-cell lung carcinoma,NSCLC)发生和发展的关系。方法应用免疫组织化学法检测45例非小细胞肺癌组织和相应癌旁组织中PTEN的表达。结果 PTEN在非小细胞癌组织和相应癌旁组织中阳性表达率分别为31.1%和66.7%,差异有统计学意义(P=0.001);PTEN表达与非小细胞肺癌分化相关(P=0.000),与患者年龄、性别,肿瘤分型、分期和淋巴结转移无关。结论 PTEN与非小细胞肺癌发生和发展相关。 Objective To investigate whether the expression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) is involved in the initiation and progression of non-small- cell lung carcinoma (NSCLC). Methods The expression of PTEN was detected in 45 paired NSCLC tumor and adjacent normal tissues by immunohistoehemistry. Results The positive ex- pression rates of PTEN in NSCLC tumor and normal tissues were 31.1% and 66.7% respec- tively, the difference was statistically significant (P = 0. 001 ). PTEN expressions correlated with the differentiation of the tumor(P = 0. 000). Conclusion Lack of PTEN expression may be involved in the initiation and progression of NSCLC.
出处 《哈尔滨医科大学学报》 CAS 北大核心 2013年第5期439-441,共3页 Journal of Harbin Medical University
基金 黑龙江省卫生厅科研课题(2011-118)
关键词 非小细胞肺癌 抑癌基因 PTEN 免疫组化 non-small-cell lung carcinoma tumor suppressor phosphatase and tensin homo-log deleted on chromosome ten immunohistochemistry
  • 相关文献

参考文献4

二级参考文献45

  • 1刘玉环,王锡智,蔡在龙,俞超芹,崔英,沙金燕.PTEN基因突变与遗传性癌症综合征及其相关疾病的研究进展[J].第二军医大学学报,2005,26(1):90-92. 被引量:5
  • 2任义,吴逸明,董海燕,魏立,吴拥军.肺癌组织中MDM2、P53蛋白的表达[J].郑州大学学报(医学版),2005,40(1):67-69. 被引量:9
  • 3李英红,徐春林,李慧慧.PTEN在非小细胞肺癌中的表达及其临床意义[J].哈尔滨医科大学学报,2006,40(5):394-396. 被引量:7
  • 4Wu Y, Zhong Z, Huber J. et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer [J]. Clin Cancer Res, 2006,12(21).6573-6584.
  • 5Smith I, Procter M, Gellber RD, et al. 2-year follow-up of trastuzumabafter Adjuvant chemotherapy in HER2-positive breast cancer; a ran-domized controlled trial[J]. Lancet, 2007, 369( 9555 )29-36.
  • 6Nahta, YUAN LX, Zhang B, et al. Insulin-like growth factor-lrecep-tor/humanepidermal growth factor receptor 2 helerodimerization con-tributes to trastuzumab resistance of breast cancer cells [J]. CancerRes, 2005;65(23) : 11118-28.
  • 7Robinsion AG, Turbin DT, homosone, et al. Molecular predictive fac- tors in patients receiving trastuzumab-based chemotherapy for metastatic disease[J]. Clin Breast Cancer, 2006;7(3):254-61.
  • 8Tang JM, He QY, Guo RX, et al. Phosphorylated Akt over expresssion and loss of PTEN expression in non-smann cell lung cancer confers poor prognosis[J]. Lung Cancer,2006,51(2): 181-191.
  • 9Goncharuk VN, del-Ronsario A, Kren L, el al.Co-downregulation of PTEN,KAI-I,and nm23-H1 tumor / metastasis suppressor proteins innon-small cell lung cancer[J]. Ann Diagn Pathol, 2004,8(1 ): 6-16.
  • 10Wang C, Yang R, Yue D, et al. Expression of FAK and PTEN in bro- chioloalveolar carcinoma and lung adenocarcinoma [J]. Lung, 2009, 187(2): 104-109.

共引文献22

同被引文献27

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部